Employees: 370
Size InBody (041830.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $380M, the 416th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩40,000 on 18 Nov 2026.
Performance Over six months the shares fell 13.1%, against -18.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue grew 21.5% over the last twelve months (peer median +7.1%); the operating margin is 21.6% (peer median 7.9%).
Valuation It trades at 11.3× forward earnings against a peer median of 19.0× (3rd cheapest of 11).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -27 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 13.0 points above its cost of capital (7.3% WACC).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩275B | ₩234B | ₩204B | ₩170B | ₩160B |
| Revenue growth | — | +14% | +20% | +6% | — |
| Gross profit | ₩214B | ₩174B | ₩153B | ₩128B | ₩117B |
| EBITDA | ₩69.1B | ₩44.7B | ₩42.7B | ₩44.3B | ₩46.1B |
| Net income | ₩41.5B | ₩30.6B | ₩33.1B | ₩36.7B | ₩33.8B |
| Free cash flow | ₩37.8B | ₩28.9B | ₩22.3B | ₩31.2B | ₩25.0B |
| Capital expenditure | ₩4.76B | ₩7.42B | ₩7.55B | ₩7.64B | ₩6.02B |
| Total debt | ₩10.6B | ₩10.3B | ₩8.42B | ₩6.08B | ₩6.40B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 041830.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.6% | -10.9% | 3rd lowest of 21 |
| 6-month return | -13.1% | -18.1% | 7th highest of 20 |
| Distance from 52-week high | -45.6% | -43.6% | 9th lowest of 21 |
| Revenue growth (TTM) | +21.5% | +7.1% | 5th highest of 21 |
| Operating margin | 21.6% | 7.9% | 5th highest of 21 |
| Forward P/E | 11.3× | 19.0× | 3rd cheapest of 11 |
| Growth the price implies (Req g, 7 yrs) | -10.3% | 5.7% | 4th least demanding of 14 |
| Growth delivered (Del g) | +16.9% | +5.6% | 5th highest of 14 |
| Hurdle (Req g minus delivered) | -27.2 pp | +1.8 pp | 4th least demanding of 14 |
| ROIC minus cost of capital | +13.0 pp | +4.7 pp | 6th highest of 20 |
| EV / EBITDA | 5.4× | 8.9× | 2nd cheapest of 10 |
| Net debt / EBITDA | -1.9× | -3.6× | 5th most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| InBody 041830.KS | South Korea | $380M | -13% | +22% | 22% | 11.3× | -10.3% | +16.9% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $379M | -26% | -11% | 5% | 37.2× | n/a | n/a |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $378M | n/a | +19% | 2% | n/a | 17.1% | +18.1% |
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | n/a | n/a | n/a |
| Taidoc Technology 4736.TW | Taiwan | $387M | 0% | 0% | 19% | n/a | -9.5% | -6.6% |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 25.3× | -4.2% | -6.0% |
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 20.3× | 24.9% | +18.8% |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $389M | -14% | +7% | -40% | n/a | n/a | n/a |
| Cerus CERS | United States | $392M | -28% | +14% | -12% | n/a | n/a | n/a |
| SEERS 458870.KS | South Korea | $392M | -70% | +174% | 37% | 15.2× | -6.3% | +247.0% |
| OrbusNeich Medical 6929.HK | Hong Kong | $394M | -15% | +16% | 23% | 8.4× | -17.6% | +15.4% |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | n/a | n/a | n/a |
| 908 Devices MASS | United States | $396M | +36% | +14% | -33% | n/a | 41.7% | +15.9% |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 18.2× | 19.1% | +0.1% |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | n/a | -13.1% | +36.8% |
| Guanhao Biotech 300238.SZ | China | $397M | -26% | -12% | 3% | n/a | n/a | n/a |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 16.4× | 5.7% | +3.4% |
| Shanghai Titan Scientific 688133.SS | China | $403M | -26% | +1% | -6% | 8.4× | n/a | n/a |
| Chison Medical Technologies 688358.SS | China | $406M | -27% | -1% | 19% | 19.8× | 9.6% | +5.6% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $354M | -23% | -8% | 17% | 36.0× | 18.4% | +4.4% |
| IVF HARTMANN VBSN.SW | Switzerland | $352M | -2% | +7% | 14% | n/a | -12.7% | -1.3% |